FUNDAMENTALS |
MarketCap: |
145 722 mill
|
EPS: |
12.48
|
P/E: |
21.79
|
Earnings Date: |
May 02, 2024 |
SharesOutstanding: |
535.92 mill
|
Avg Daily Volume: |
2.94 mill
|
RATING
2024-04-22 |
S
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 21.79 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
1.13x
|
Company: PE 21.79 | industry: PE 19.30
|
DISCOUNTED CASH FLOW VALUE |
$471.87
(73.54%)
$199.96
|
Date: 2024-04-22
|
Expected Trading Range (DAY) |
$ 266.52 - 277.31
( +/- 1.98%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-18 | Santos Esteban | Sell | 6 137 | Common Stock |
2024-03-18 | Reese David M | Sell | 6 202 | Common Stock |
2024-03-18 | Miller Derek | Sell | 475 | Common Stock |
2024-03-18 | Khosla Rachna | Sell | 438 | Common Stock |
2024-03-18 | Grygiel Nancy A. | Sell | 703 | Common Stock |
INSIDER POWER |
58.90
|
Last
97 transactions |
Buy:
472 102 | Sell:
97 922 |
Forecast:
16:00 - $271.69
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $271.69
Forecast 2: 16:00 - $271.69
Forecast 3: 16:00 - $271.69
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$271.91 (1.11% )
|
Volume |
2.14 mill
|
Avg. Vol. |
2.94 mill
|
% of Avg. Vol |
72.79 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For AMGN
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:35 | sell | $293.50 | N/A | Active |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.